Literature DB >> 12118126

Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL.

M Clayer1, S Bouralexis, A Evdokiou, S Hay, G J Atkins, D M Findlay.   

Abstract

Soft tissue sarcomas are less responsive to conventional chemotherapy when compared to bone sarcomas. We investigated the possibility of enhancing the efficacy of chemotherapy by utilising the recently identified cytokine, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with standard chemotherapeutic agents. Fresh human soft tissue sarcomas (rhabdomyosarcoma, fibrosarcoma, malignant fibrous histiocytoma) were obtained at biopsy and dispersed tumour cells were incubated in cell culture with standard cytotoxic agents, either as single agents or in combination with TRAIL. The chemotherapeutic agents were, at best, moderately effective, in terms of induction of cellular apoptosis, although the fibrosarcoma was completely unresponsive to all single agents. TRAIL alone had no effect on any sarcoma cell culture. In contrast, the addition of TRAIL and drug together produced a significant increase in sarcoma cell apoptosis, with TRAIL and doxorubicin the most effective combination.

Entities:  

Year:  2001        PMID: 12118126     DOI: 10.1177/230949900100900205

Source DB:  PubMed          Journal:  J Orthop Surg (Hong Kong)        ISSN: 1022-5536            Impact factor:   1.118


  6 in total

Review 1.  The promise of TRAIL--potential and risks of a novel anticancer therapy.

Authors:  Ronald Koschny; Henning Walczak; Tom M Ganten
Journal:  J Mol Med (Berl)       Date:  2007-04-17       Impact factor: 4.599

2.  TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Authors:  Suizhao Wang; Wenhong Ren; Jeffery Liu; Guy Lahat; Keila Torres; Gonzalo Lopez; Alexander J Lazar; Andrea Hayes-Jordan; Kebin Liu; Jim Bankson; John D Hazle; Dina Lev
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

3.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

4.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

Authors:  L Pukac; P Kanakaraj; R Humphreys; R Alderson; M Bloom; C Sung; T Riccobene; R Johnson; M Fiscella; A Mahoney; J Carrell; E Boyd; X T Yao; L Zhang; L Zhong; A von Kerczek; L Shepard; T Vaughan; B Edwards; C Dobson; T Salcedo; V Albert
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

5.  Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27.

Authors:  G Mellier; D Liu; G Bellot; A Lisa Holme; S Pervaiz
Journal:  Cell Death Dis       Date:  2013-10-31       Impact factor: 8.469

Review 6.  Death receptors as targets for anti-cancer therapy.

Authors:  Kerstin Papenfuss; Stefanie M Cordier; Henning Walczak
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.